This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in HFD aged rats: Study

Researchers validate an ultra-sensitive personalized circulating tumor DNA assay
Aging-related serum changes in insulin resistance and lipogenesis. (A) Glucose levels, (B) insulin levels, and (C) HOMA-IR scores were determined. (D) FFA (free fatty acid), (E) TG, (F) HDL, and (G) LDL levels in the serum of HFD-fed aged rats (each n = 6). Results of one-factor ANOVA: *p < 0.05, **p < 0.01 vs. young rats; #p < 0.05 vs. old rats. Credit: Aging (2024). DOI: 10.18632/aging.205610

A new research paper titled "FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet" has been published in Aging.

FoxO6, an identified factor, induces hyperlipidemia and hepatic steatosis during aging by activating hepatic lipoprotein secretion and lipogenesis leading to increased ApoC3 concentrations in the bloodstream. However, the intricate mechanisms underlying hepatic steatosis induced by elevated FoxO6 under hyperglycemic conditions remain intricate and require further elucidation.

In this new study, researchers Dae Hyun Kim, Seulah Lee, Sang Gyun Noh, Jaewon Lee, and Hae Young Chung from Pusan National University aimed to delineate the regulatory pathway involving ApoC3 controlled by FoxO6 and its resultant functional impacts.

The researchers explain, "[...] we employed a spectrum of models including liver cell cultures, aged rats subjected to HFD, overexpressing FoxO6 (FoxO6-Tg), and FoxO6 knockout mice (FoxO6-KO)."

Their findings indicate that FoxO6 triggered ApoC3-driven lipid accumulation in the livers of aged rats on an HFD and in FoxO6-Tg, consequently leading to hepatic steatosis and hyperglycemia. Conversely, the absence of FoxO6 attenuated the expression of genes involved in lipogenesis, resulting in diminished hepatic lipid accumulation and mitigated hyperlipidemia in murine models.

Additionally, the upregulation of FoxO6 due to elevated led to increased ApoC3 expression, consequently instigating cellular triglyceride mediated lipid accumulation. The transcriptional activation of FoxO6 induced by both the HFD and high glucose levels resulted in hepatic steatosis by upregulating ApoC3 and genes associated with gluconeogenesis in aged rats and liver cell cultures.

"Our conclusions indicate that the upregulation of ApoC3 by FoxO6 promotes the development of hyperlipidemia, hyperglycemia, and hepatic steatosis in vivo, and in vitro. Taken together, our findings underscore the significance of FoxO6 in driving and specifically under hyperglycemic states by enhancing the expression of ApoC3 in aged rats," the researchers conclude.

More information: Dae Hyun Kim et al, FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet, Aging (2024). DOI: 10.18632/aging.205610

Provided by Impact Journals LLC
Citation: FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in HFD aged rats: Study (2024, March 20) retrieved 22 May 2024 from https://medicalxpress.com/news/2024-03-foxo6-apoc3-upregulation-hepatic-steatosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Hepatic TRPC3: An emerging regulator of alcohol-associated liver disease

 shares

Feedback to editors